Lu-177-DOTATATE
Phase 2Small molecule
Lu-177-DOTATATE is one of 60 small molecule programs targeting Paraganglioma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
60 competitors in Paraganglioma
#DrugCompanyPhaseTrials
1Erivedge
RocheApproved
Vimpat
UCBApproved
Thalomid
Bristol-Myers SquibbApproved
Velban
Eli LillyApproved
Camptosar
PfizerApproved
Keppra
UCBApproved
Taxol
TevaApproved
Kisqali
NovartisApproved
Afinitor
NovartisApproved
Remeron
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lu-177-DOTATATE. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNational Cancer Institute (NCI)